| |
|
|
Debunking
the urban legends of |
|
URINARY
NEUROTRANSMITTER TESTING |
|
The following statements are
true |
|
| |
|
Pathologist Thomas
Uncini, MD |
|
Director and Owner of DBS Labs |
Testing is of no value
in making a diagnosis with diseases |
|
Board certified in Anatomic and Clinical Pathology |
|
associated with low levels of neurotransmitters |
|
Board certified in forensic pathology.
|
Base line
testing prior to starting amino acids is of no value. |
|
Chief of Pathology
Fairview University Hospital Mesabi |
Base line
testing prior to taking amino acid precursors has |
|
Chief of Pathology Cook Community Hospital |
no correlation with testing performed when the patient |
|
Director Fairview University Medical Center
Hospital Lab |
is taking amino acid precursors. |
|
Director Cook Community Hospital Lab |
Testing is of no value
in treating disease symptoms if the |
|
St. Louis County Medical Examiner |
goal is merely to establish therapeutic or optimal levels. |
| Director
DBS Medical Labs |
Testing
is only of value when the goal of treatment is to |
| |
establish the urinary serotonin and dopamine in "The |
|
DBS Brochure |
Phase 3 Therapeutic Response". |
|
|
|
Are the majority of your patients
achieving true relief with amino acids? |
|
If not, we
have a medical education approach that you should look at closely. |
|
|
|
|
|
DBS Labs only
deals with and gives advice to licensed health care providers. |
| |
|
